|
|
|
| Effects of Alprostadil Combined with Fenofibrate on Urinary Podocyte Associated Proteins and Renal Function Protection in Patients with Diabetic Nephropathy |
| SUN Feng, ZHANG Rui, ZHAO Yusong |
| Affiliated Hospital of Yangzhou University, Jiangsu Yangzhou 25002, China |
|
|
|
|
Abstract Objective: To investigate the effect of alprostadil combined with fenofibrate on urinary podocyte related protein and renal function protection in diabetic nephropathy patients. Methods: 112 patients with diabetic nephropathy were divided into control group (n=54) and observation group (n=58) according to simple random method. The control group was treated with fenofibrate, while the observation group was treated with alprostadil on the basis of the control group. The clinical effects, and the changes of urinary podocyte related protein, renal function, renal blood flow parameters and blood glucose indexes before and after treatment, and adverse reactions of the two groups were compared. Results: After treatment, the total effective rate of the observation group was higher than that of the control group (P<0.05). Before treatment, there was no significant difference in urinary podocyte related protein, renal function, renal blood flow parameters and blood glucose indexes between the two groups (P>0.05). After treatment, urinary podocyte related protein and renal function indexes of the two groups decreased and renal blood flow parameter indexes increased compared with those before treatment. the difference between the above indexes before and after treatment in the observation group was significantly higher than that in the control group (P<0.05). There was no significant change in blood glucose index between the two groups after treatment (P>0.05). There was no significant difference in total rate of adverse reactions between the two groups (P>0.05). Conclusion: Alprostadil combined with fenofibrate can improve the curative effect of diabetic nephropathy, reduce the level of urinary podocyte related protein and protect renal function.
|
|
|
|
|
|
[1] Shimizu M, Furuichi K, Wada T. Epidemiology and pathogenesis of diabetic nephropathy[J]. Nihon Jinzo Gakkai Shi, 2017,59(2):43~49.
[2] Yaribeygi H, Mohammadi MT, Rezaee R, et al. Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy[J].Cell Biochem, 2018,119(9):7458~7469.
[3] 柴冬梅.前列地尔对糖尿病肾病患者血清炎症因子、肾脏纤维化指标的影响[J].现代医学,2017,45(9):1301~1305.
[4] 林兵英,罗晓燕,方周宾,等.尿液中的足细胞标志蛋白定量检测应用于糖尿病和糖尿病肾病诊断中的价值比较[J].标记免疫分析与临床,2019,26(4):70~72.
[5] 王蔚文.临床疾病诊断与疗效判断标准[M].科技技术文献出版社,2010.371~372.
[6] Tnnies T,Stahl-Pehe A, Baechle C, et al. Diabetic nephropathy and quality of life among youths with long-duration type 1 diabetes: a population-based cross-sectional study[J]. Pediatr Diabetes, 2019,20(5):613~621.
[7] 刘超,刘彦,李强,等.前列地尔对早期糖尿病肾病患者肾功能、氧化应激及免疫功能的影响[J].中国医师杂志,2017,19(3):396~398,402.
[8] 刘楠,李国铨,钟良宝,等.前列地尔联合贝那普利对糖尿病肾病患者尿蛋白、白蛋白水平的影响[J].海南医学,2017,28(16):2602~2604.
[9] 张馨元,米焱,王彩丽.足细胞损伤与糖尿病肾病[J].肾脏病与透析肾移植杂志,2019,28(2):161~165.
[10] Bjornstad P, Lovshin JA, Lytvyn Y,et al. Adiposity impacts intrarenal hemodynamic function in adults with long-standing type 1 diabetes with and without diabetic nephropathy: results from the canadian study of longevity in type 1 diabetes[J]. Diabetes Care, 2018,41(4):831~839. |
|
|
|
2020, Vol. 26 
